On the morning of December 16, a delegation from the General Office of the Hospital Authority of the Hong Kong Special Administrative Region, including Dr. Xie Dazhi , Senior Administrative Manager of the Integrated Clinical Services Department, Ms.Ou Kunye, Manager of the Clinical Services Department, Ms.Yang Huimin, Senior Pharmacist of the Hospital Authority, Dr. Chen Shouren, Consultant in Hematology at Queen Mary Hospital, The University of Hong Kong, Dr. Wang Shaoming, Consultant in Hematology at Prince of Wales Hospital, The Chinese University of Hong Kong, and Dr. Liu Shimin, Consultant in Hematology at Queen Elizabeth Hospital, visited Shenzhen Cell Valley for an exchange visit. The delegation was warmly received by our company's Chairman Professor Shi Yuanyuan, Chief Scientist Professor Wang Jianxun, Business Director Wei Zheng, Chairman's Assistant Fu Yuchen, Marketing Director Sun Rui, and Director of the General Office Wang Lu.

Under the guidance of Professor Shi Yuanyuan, Chairman of the Board, the visiting delegation toured the Digital Intelligence Exhibition Hall, GMP R&D and Production Laboratory, and Quality Management Laboratory of Shenzhen Cell Valley. They gained firsthand insights into the latest research achievements and laboratory layout in the field of cell therapy at Shenzhen Cell Valley, as well as a profound understanding of the corporate culture of the institution.

During the subsequent symposium,Dr. Xie Dazhi stated that the purpose of this visit and exchange was to understand the core advantages, clinical cases, and data references of Shenzhen Cell Valley in the field of CAR-T cell therapy. He also expressed the hope to learn about the regulatory requirements and approval processes for CAR-T cell products in mainland China, as well as the application procedures for import and export permits, through Shenzhen Cell Valley. This would facilitate discussions on the development and collaboration between Shenzhen and Hong Kong in the field of cell therapy.

Chairman Shi Yuanyuan first comprehensively introduced the core advantages of Shenzhen Cell Valley, including the underlying technology of viral vectors for cell therapy and industrial-scale production technology for cell preparation. The core assets are the R&D and production talent team personally cultivated by the two founders. In terms of clinical applications, Shenzhen Cell Valley has established substantive and comprehensive collaborations with multiple hospitals. To date, it has successfully prepared GMP-grade CAR-T cell products targeting BCMA, CD19, CD19/CD22, CD7, CD38, and other targets, treating over 100 patients with various hematologic malignancies such as multiple myeloma, lymphoma, and leukemia. The success rate of autologous CAR-T cell preparation in patients is 100%. For patients who failed prior treatments and experienced relapse or drug resistance, the clinical efficacy rate of CAR-T cell therapy exceeds 78%.

Chairman Shi Yuanyuan introduced to Hong Kong guests that Shenzhen Cell Valley has established a wholly-owned subsidiary in Hong Kong—Hong Kong Cell Valley Biomedical Co., Ltd.——to provide more convenient services for future collaboration with Hong Kong hospitals and enterprises. In the second half of this year, Shenzhen Cell Valley declared special items for entry and exit to Shenzhen Customs and successfully passed the risk assessment report for viral vector products. It also participated in the recognition of the "white list" and positive item list for pilot enterprises (institutions) of special items for entry and exit in the biopharmaceutical sector in Shenzhen. In response to the recent joint policy issued by three national ministries regarding the CGT (Cell and Gene Therapy) sector in the Guangdong Free Trade Zone, Shenzhen Cell Valley is establishing a medical service institution in the Qianhai Free Trade Zone to fully leverage national policies and promote the development of the cell therapy industry in both Shenzhen and Hong Kong.

Dr. Xie Dazhi expressed high recognition of the strategic development plan formulated by Shenzhen Cell Valley, the core technologies mastered, and clinical application cases. He also introduced the public healthcare management institution of the Hong Kong Special Administrative Region, where the Hospital Authority of Hong Kong (HAHK) is a statutory body under the Department of Health of the Hong Kong Special Administrative Region, directly managing all public hospitals and related medical institutions. Currently, CAR-T cell therapy in Hong Kong public hospitals began in May 2021, with three CAR-T cell therapy centers established at Queen Mary Hospital, Prince of Wales Hospital, and Hong Kong Children's Hospital, having treated over 100 patients to date. With the increasing availability of products and the clinical demand for unregistered indications, Hong Kong is actively exploring the introduction of more products to meet the needs, while considering the introduction of products from the Chinese mainland, striving to expand the service scope of CAR-T cell therapy, and contemplating the referral of patients to the mainland for CAR-T treatment and fostering exchanges and cooperation. Dr. Wang Shaoming, Dr. Chen Shouren, and Dr. Liu Shimin, three consultant physicians, also highly recognized Shenzhen Cell Valley's advantages in cell preparation quality control and discussed in detail the recent collaboration on viral vectors and future joint construction of cell preparation centers.

At the conclusion of the symposium, both parties reached a consensus to leverage the resource-sharing platforms between Hong Kong and Shenzhen to advance collaborative efforts in scientific research, experimental studies, and clinical applications. This initiative aims to jointly promote the development of cell therapy in Shenzhen and Hong Kong, thereby providing higher-quality services for residents in both regions and truly realizing the vision and mission of "Cells benefiting all, genes creating the future."